Effect of ICL-V4c Implantation in Treatment of Ultra-High Myopia
Ying Xiong, Xiuli Sun, Yingyan Mao, Jing Li, Kai Cao, Jingshang Zhang, Jinda Wang, Xiuhua Wan
Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing 100005, China
Abstract： Objective: To observe the safety and effectiveness of ICL-V4c implantation in the treatment of ultra-high myopia over -10 D, and to explore the relationship and rules between the improvement of vision (△LogMAR) and preoperative spherical diopter (SD). Methods: This was a retrospective study. Eight hundred and two patients (1 380 eyes) with ultra-high myopia were treated by ICL-V4c implantation in Beijing Tongren Hospital from December 2016 to January 2020. The preoperative SD was -23.50 D≤SD≤-6.00 D (mean -11.54±3.59 D). The patients were divided into group A (-10 D<SD≤-6 D) and group B (-23.5 D ≤SD≤-10 D) according to their preoperative SD. Group B was further divided into five sub groups: B1 (-13 D<SD≤-10 D), B2 (-16 D<SD≤-13 D), B3 (-19 D<SD≤-16 D), B4 (-22 D<SD≤-19 D) and B5 (-23.5 D≤SD≤-22 D). The preoperative and postoperative visual acuity at 1 week and 2 months and improvement in visual acuity and intraocular pressure of the patients were analyzed by Kruskal-Wallis test and Chi-square test. Results: The postoperative SD and best corrected visual acuity (BCVA) of patients in group B were significantly improved (P<0.001). Both mean safety and effectivity indices were >1. There was a significant correlation between △LogMAR and group (P<0.001). △LogMAR in the B3 and B4 groups was significantly higher than that in A, B1 and B2 groups (adjusted, P<0.001). The intraocular pressure (IOP) in group B was higher than that in group A (P<0.001), and the proportion of postoperative high IOP was higher (P=0.008). Conclusions: ICL implantation is safe and effective for patients with ultra-high myopia over -10 D, but the long-term effect needs further explorations. The improvement of BCVA in patients with -22 D≤SD≤-16 D was higher than that of patients with -16 D<SD≤-6 D.
Hiraoka T, Sekine Y, Okamoto F, et al. Safety and efficacy following 10-years of overnight orthokeratology for myopia control. Ophthalmic Physiol Opt, 2018, 38(3): 281-289. DOI: 10.1111/opo.12460.
[2]
Yan Z, Miao H, Zhao F, et al. Two-year outcomes of visian implantable collamer lens with a central hole for correcting high myopia. J Ophthalmol, 2018, 2018: 8678352. DOI: 10.1155/2018/8678352.
[3]
Qin Q, Wu Z, Bao L, et al. Evaluation of visual quality after EVO-ICL implantation for hypermyopia: An observational study. Medicine (Baltimore), 2019, 98(44): e17677. DOI: 10.1097/MD.0000000000017677.
[4]
Chen M, Long Q, Gu H, et al. Accommodation changes after visian implantable collamer lens with central hole for high myopia: A STROBE-compliant article. Medicine (Baltimore), 2019, 98(28): e16434. DOI: 10.1097/MD.0000000000016434.
Nakamura T, Isogai N, Kojima T, et al. Posterior chamber phakic intraocular lens implantation for the correction of myopia and myopic astigmatism: A retrospective 10-year followup study. Am J Ophthalmol, 2019, 206: 1-10. DOI: 10.1016/ j.ajo.2019.04.024.
[8]
Han T, Shang J, Zhou X, et al. Refractive outcomes comparing SMILE and FS-LASIK for high myopia. J Cataract Refract Surg, 2020, 46(3): 419-427. DOI: 10.1097/j.jcrs.0000000000000075.
[9]
Kamiya K, Shimizu K, Igarashi A, et al. Posterior chamber phakic intraocular lens implantation: Comparative, multicentre study in 351 eyes with low-to-moderate or high myopia. Br J Ophthalmol, 2018, 102(2): 177-181. DOI: 10.1136/bjophthalmol- 2017-310164.
[10]
Leveziel N, Marillet S, Dufour Q, et al. Prevalence of macular complications related to myopia-Results of a multicenter evaluation of myopic patients in eye clinics in France. Acta Ophthalmol, 2020, 98(2): e245-e251. DOI: 10.1111/aos.14246.
[11]
Miao H, Chen X, Tian M, et al. Refractive outcomes and optical quality after implantation of posterior chamber phakic implantable collamer lens with a central hole (ICL V4c). BMC Ophthalmol, 2018, 18(1): 141. DOI: 10.1186/s12886-018-0805-3.
[12]
Tang Y, Ye J. Phakic posterior chamber intraocular lens with a central hole in treating patients with moderate to high myopia: A Meta-Analysis. J Ophthalmol, 2019, 2019: 9496326. DOI: 10.1155/2019/9496326.
[13]
Takahashi M, Kamiya K, Shoji N, et al. Intentional undercorrection by implantation of posterior chamber phakic intraocular lens with a central hole (Hole ICL) for early presbyopia. Biomed Res Int, 2018, 2018: 6158520. DOI: 10.1155/2018/6158520.
[14]
Alfonso JF, Fernandez-Vega-Cueto L, Alfonso-Bartolozzi B, et al. Five-year follow-up of correction of myopia: Posterior chamber phakic intraocular lens with a central port design. J Refract Surg, 2019, 35(3): 169-176. DOI: 10.3928/1081597X- 20190118-01.
浙公网安备 33030202001892号